drugset / Trial / NCT07142642
A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants
RandomizedParallel-groupDouble-blindBasic science
Summary
The primary objective of the study is to evaluate the pharmacokinetics (PK) of teprotumumab after a single intravenous (IV) infusion of teprotumumab in healthy Chinese participants.
Timeline
- Start
- 2025-08-26
- Primary completion
- 2025-11-22
- Completion
- 2026-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Teprotumumab | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.